Evidence map›Paper›PMID 33953218›Full record

ArticleScientific reports2021

Cross-sectional analysis of the Parkinson's disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life.

Daniel J van Wamelen, Anna Sauerbier, Valentina Leta, Carmen Rodriguez-Blazquez, Cristian Falup-Pecurariu, Mayela Rodriguez-Violante, Alexandra Rizos, Y Tsuboi, Vinod Metta, Roongroj Bhidayasiri and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Early parkinson's disease: levodopa requirements are associated with the striatal DaT-uptake.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Demographic and Clinical Profiles of Parkinson's Disease in India: Observations from a Nation-Wide Multicenter Study.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Daniel J van WamelenDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Daniel.van_Wamelen@kcl.ac.uk.
Anna SauerbierDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Valentina LetaDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Carmen Rodriguez-BlazquezNational Center of Epidemiology, Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
Cristian Falup-PecurariuDepartment of Neurology, Faculty of Medicine, County Emergency Clinic Hospital, Transilvania University, Braşov, Romania.
Mayela Rodriguez-ViolanteMovement Disorders Unit, Instituto Nacional de Neurologia y Neurocirugía, Mexico, DF, Mexico.
Alexandra RizosDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Y TsuboiDepartment of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Vinod MettaParkinson's Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London, UK.
Roongroj BhidayasiriChulalongkorn University Hospital, Bangkok, Thailand.
Kalyan BhattacharyaFormerly RG Kar Medical College and Institute of Neuroscience, Kolkata, India.
Rupam BorgohainNizam's Institute of Medical Sciences, Hyderabad, India.
L K PrashanthCenter for Parkinson's Disease and Movement Disorders Clinic, Vikram Hospitals, Bangalore, India.
Raymond RosalesUniversity of Santo Tomas Hospital, Manila, Philippines.
Simon LewisForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia.
Victor FungMovement Disorders Unit, Neurology Department, Westmead Hospital, Sydney, Australia.
Madhuri BehariDepartment of Neurology, Cardiothoracic and Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India.
Vinay GoyalDepartment of Neurology, All India Institute of Medical Sciences, New Delhi, India.
Asha KishoreSree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India.
Santiago Perez LloretBiomedical Research Center, Interamerican Open University (CAECIHS-UAI), National Research Council (CONICET), Buenos Aires, Argentina.
Pablo Martinez-MartinCenter for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
K Ray ChaudhuriDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growing evidence suggests that non-motor symptoms (NMS) in Parkinson's disease (PD) have differential progression patterns that have a different natural history from motor progression and may be geographically influenced. We conducted a cross-sectional analysis of 1607 PD patients of whom 1327 were from Europe, 208 from the Americas, and 72 from Asia. The primary objective was to assess baseline non-motor burden, defined by Non-Motor Symptoms Scale (NMSS) total scores. Other aims included identifying the factors predicting quality of life, differences in non-motor burden between drug-naïve and non-drug-naïve treated patients, and non-motor phenotypes across different geographical locations. Mean age was 65.9 ± 10.8 years, mean disease duration 6.3 ± 5.6 years, median Hoehn and Yahr stage was 2 (2-3), and 64.2% were male. In this cohort, mean NMSS scores were 46.7 ± 37.2. Differences in non-motor burden and patterns differed significantly between drug-naïve participants, those with a disease duration of less than five years, and those with a duration of five years or over (p ≤ 0.018). Significant differences were observed in geographical distribution (NMSS Europe: 46.4 ± 36.3; Americas: 55.3 ± 42.8; Asia: 26.6 ± 25.1; p < 0.001), with differences in sleep/fatigue, urinary, sexual, and miscellaneous domains (p ≤ 0.020). The best predictor of quality of life was the mood/apathy domain (β = 0.308, p < 0.001). This global study reveals that while non-motor symptoms are globally present with severe NMS burden impacting quality of life in PD, there appear to be differences depending on disease duration and geographical distribution.

Indexed as

Quality of LifeAgedApathyCross-Sectional StudiesFatigueFemaleHumansLongitudinal StudiesMaleMiddle AgedParkinson DiseaseSeverity of Illness IndexSleepSurveys and Questionnaires

Identifiers

PMID33953218
PMCPMC8100281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.